Biotech entity
Negative sentiment reaches 14% here, compared with 15% across the 519-story beat baseline for the same window. That works out to roughly 0.4 stories per week across a 137-day span. Their average consequence score of 6.9 runs above the beat's 6.1 for that window.
Last mentioned: Jun 28, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 72 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Negative sentiment reaches 14% here, compared with 15% across the 519-story beat baseline for the same window. That works out to roughly 0.4 stories per week across a 137-day span. Their average consequence score of 6.9 runs above the beat's 6.1 for that window. Of the tracked stories, 1 of 7 also mention Biotech Industry, the most common co-covered peer. pharma accounts for 3 of the 7 tracked stories, while 2 other categories carry the remainder. They are better corroborated than the beat average, carrying 4.1 original sources each against 3.5 for the same window. We currently track 7 Biotech stories that mention U.S. Food and Drug Administration, published between February 18, 2026 and July 4, 2026.
Computed from the 7 stories linked to this entity, with beat comparisons drawn from all 519 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering U.S. Food and Drug Administration. Shared-story counts are live from our verified record — not editorial picks.
Target Commercialization
Anticipated EU launch for iopofosine I 131 treatment of WM.
EMA Submission
Target window for filing the CMA for iopofosine I 131 in the European Union.
CLR 125 Data Readout
Expected early data from the Phase 1b study in Triple Negative Breast Cancer.
JPM Earnings
JPMorgan Chase reports Q1 results amid regulatory and legal headwinds.
FDA Decision Date
Expected regulatory ruling on orforglipron oral weight loss drug.
Phase III Initiation
First patient dosed at Peking Union Medical College Hospital in China.
Annual Results Announcement
CEO James Caruso provides corporate updates and confirms regulatory timelines.
Regulatory Designations
HMI-115 receives FDA Fast Track and NMPA Breakthrough Therapy designations.
Trial Expansion
Continued enrollment across global multicenter sites for the 24-week study.
Fiscal Year End
Cellectar concludes a year focused on pipeline execution and supply chain strengthening.
Phase II Completion
Global multicenter Phase II trial results published in The Lancet showing efficacy and safety.
Zepbound Approval
FDA expands tirzepatide approval to include chronic weight management.
Mounjaro Launch
Tirzepatide enters the market for Type 2 Diabetes treatment.
Philip Morris’s ZYN secured the first FDA modified risk orders for a nicotine pouch, authorizing reduced‑exposure marketing for 10 flavors. The decision sets a regulatory benchmark for oral nicotine products.
Hope Medicine Inc. has initiated dosing in its Phase III clinical trial for HMI-115, a first-in-class non-hormonal monoclonal antibody for endometriosis. This milestone marks the first time a non-hormonal treatment for this condition has reached Phase III development globally, offering a potential alternative to traditional hormonal therapies.
Eli Lilly (LLY) is approaching a pivotal April 10 regulatory milestone for orforglipron, its experimental oral GLP-1 receptor agonist, as it seeks to expand its $11 billion weight-loss portfolio. While the broader market faces volatility from the banking sector's upcoming earnings on April 14, the biotech industry is laser-focused on the potential shift from injectable to oral metabolic therapies.
Texas Governor Greg Abbott has launched a formal investigation into the safety and security of medical devices manufactured in China and used within the state's healthcare system. The move signals a growing trend of state-level scrutiny over international medical supply chains and potential vulnerabilities in critical healthcare infrastructure.
Cellectar Biosciences has confirmed its trajectory for a Q3 2026 regulatory submission to the EMA for its lead radiotherapeutic, iopofosine I 131. The company is simultaneously advancing its Phase 1b study of CLR 125 in triple-negative breast cancer, marking a significant expansion of its phospholipid drug conjugate platform.
The U.S. Food and Drug Administration is introducing a landmark performance-based bonus system for staff members who complete drug application reviews ahead of schedule. This shift toward private-sector incentive models aims to clear regulatory backlogs and accelerate patient access to new therapies.
The U.S. Food and Drug Administration is moving to eliminate the long-standing requirement for two pivotal clinical trials for new drug approvals. This regulatory shift aims to significantly reduce the time and cost of drug development, prioritizing faster patient access to innovative therapies.
Source: dailybulletin.com · baltimoresun.com
U.S. Food and Drug Administration is linked from 7 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
